Medtronic's stock has been an underwhelming investment to hold on to in recent years. While it's up around 4% this year, over ...

Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, ...

The new diabetes company will be predominantly business-to-consumer, while Medtronic’s model was more business-to-business.

Medtronic upgraded to 'Strong Buy' with $104 fair value. Diabetes spin-off boosts focus on core markets, driving growth, ...

Medical device manufacturer Medtronic (MDT) plans to separate its diabetes business into a stand-alone company, ...

CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.

Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a standalone company. The new diabetes company will focus on accelerating ...

The medical device maker has been working to turn around the division over the last few years.

Today, big tech companies team up with specialty societies to help doctors.

Under Medtronic’s plan, the new unnamed company will also be publicly traded, Medtronic said. The diabetes business generated nearly $2.8 billion in sales in its most recent fiscal year ...